ライフサイエンスコーパス: double-blind trial

1 = 30) or placebo (n = 31) for 7 days in this double-blind trial.

2 olitis has not been studied in a controlled, double-blind trial.

3 hritis (TEAR) study is a 2-year, randomized, double-blind trial.

4 untries in a randomized, placebo-controlled, double-blind trial.

5 multicentre, randomised, placebo-controlled, double-blind trial.

6 mized to GA or placebo (PBO) in this 3-year, double-blind trial.

7 andomized, multi-center, placebo-controlled, double-blind trial.

8 nrolled in a placebo-controlled, randomized, double-blind trial.

9 er 100 mg FeSO(4) or a placebo for 6 wk in a double-blind trial.

10 withdrawal, multicenter, placebo-controlled, double-blind trial.

11 and C (1000 mg per day) or to placebos in a double-blind trial.

12 SO(4) or a placebo twice daily for 6 wk in a double-blind trial.

13 or fluoxetine were assessed after a 6-week, double-blind trial.

14 or to placebo, during the subsequent 28-week double-blind trial.

15 ranspupillary thermotherapy in a randomized, double-blind trial.

16 dition to standard therapy in a multicenter, double-blind trial.

17 heir conventional neuroleptic for an 8-week, double-blind trial.

18 were compared in a multicenter, randomized, double-blind trial.

19 unts <100/mm3 were enrolled in a randomized, double-blind trial.

20 th that of standard therapy in a randomized, double-blind trial.

21 l Infections) was a prospective, randomized, double-blind trial.

22 abstinence were entered into this crossover, double-blind trial.

23 t failure and reduced ejection fraction in a double-blind trial.

24 disease in a randomized, placebo-controlled, double-blind trial.

25 hey were based on the results of randomized, double-blind trials.

26 g) once daily for 6 or 9 months in 4 similar double-blind trials.

27 g, proof of efficacy will require randomized double-blind trials.

28 of findings from open-label series and small double-blind trials.

29 am induction in a single center, randomized, double-blinded trial.

30 en using permuted-block randomisation in non-double-blinded trials.

31 For this double-blind trial, 10,305 subjects 18 years of age or o

32 In a double-blind trial, 157 inpatients with a history of sub

33 In a three-year, double-blind trial, 160 patients with coronary disease,

34 In a 6-week double-blind trial, 20 schizophrenic patients received p

35 at of a control.In a randomized, controlled, double-blinded trial, 220 participants aged 18-60 y with

36 In a double-blind trial, 225 adults underwent randomization.

37 In this randomized, 2 x 2 factorial, double-blind trial, 2400 infants were randomly assigned

38 In this randomized, placebo-controlled, double-blind trial, 25 patients were treated with either

39 In a multicenter, randomized, controlled, double-blind trial, 340 HIV-1-positive adults not on ant

40 In a randomized, placebo-controlled, double-blind trial, 35 patients with early scleroderma r

41 In this randomized, double-blinded trial, 37 female subjects aged 19-35 y wi

42 In a double-blind trial, 499 patients aged 14 years or older

43 Data were pooled from 10 double-blind trials (6699 patient-years of follow-up).

44 In the randomized double-blind trial, 7 of 10 volunteers receiving a lacto

45 In a double-blind trial, 73 patients (median age, 63 years; 2

46 In a prospective, double-blind trial, acute liver failure patients without

47 In this multicenter, randomized, double-blind trial, adolescent and adult patients (age,

48 In a randomized, double-blind trial, adults with acute bacterial skin and

49 In a 12-week randomized, double-blind trial, ALS and MS patients with clinically

50 abatrin (N=50) or placebo (N=53) in a 9-week double-blind trial and 4-week follow-up assessment.

51 Dar es Salaam, Tanzania, were enrolled in a double-blind trial and provided daily supplements of pre

52 Treatment with pilocarpine is effective in double-blind trials and low dose oral alpha interferon l

53 Larger scale, randomized, double-blind trials are needed to validate the role of s

54 This randomized double-blind trial assessed the potential additional imp

55 Two randomized, double-blinded trials assessed the safety and immunogeni

56 is the first placebo controlled, randomized double blinded trial assessing the efficacy and tolerabi

57 We did a randomised, placebo-controlled, double-blind trial at 29 UK secondary and tertiary hospi

58 We performed a double-blind trial at a tertiary care hospital in India.

59 We did this multicentre, double-blind trial at four general hospitals in northern

60 against influenza in two placebo-controlled, double-blind trials at different U.S. sites during the w

61 sed, parallel-treatment, placebo-controlled, double-blind, trial at 81 sites in the Europe and the US

62 r-infant pairs were enrolled in a randomised double-blind trial between September, 2001, and October,

63 In this multicentre, double-blind trial, between Oct 21, 2013, and Oct 30, 20

64 oup (BIG) conducted a randomized, phase III, double-blind trial, BIG 1-98, which enrolled 8,010 postm

65 TIENTS: Two phase 3 multicenter, randomized, double-blind trials carried out from 2007 to 2010.

66 In this parallel placebo-controlled double-blinded trial, children aged 3-12 years with >4 w

67 This randomized, double-blind trial compared a regimen of 7 to 12 days of

68 A 3-week, randomized, double-blind trial compared flexibly dosed olanzapine (5

69 This multicenter, randomized, double-blind trial compared fluconazole (N = 295) versus

70 Randomized, controlled, double-blind trial compared RRR-alpha-tocopherol (1200 I

71 This randomized double-blind trial compared the impact of PCV13 versus P

72 We conducted a randomized, double-blind trial comparing a sirolimus-eluting stent w

73 ional Review Board (IRB)-approved randomised double-blind trial comparing active to sham deep brain s

74 A 24-week randomized double-blind trial comparing ALC (3,000 mg per day) with

75 We performed a post hoc analysis of a double-blind trial comparing fondaparinux with placebo.

76 We conducted a double-blind trial comparing gemfibrozil (1200 mg per da

77 d of a prospective, randomized, multicenter, double-blind trial comparing polymer-free SES with place

78 We conducted a randomized, double-blind trial comparing salmeterol at a dose of 50

79 spB in virulence, we conducted a randomized, double-blind trial comparing the ability of wild-type EP

80 000 mg naproxen/day and then began a 6-week, double-blind trial comparing treatment with HCQ at 400 m

81 The study was a randomized, double-blind trial conducted at 30 hemodialysis units at

82 phase 1/2, dose-finding, placebo-controlled, double-blind trial conducted at the University Hospitals

83 Randomized, double-blind trial conducted in 3 sites in the Pacific N

84 In a randomized, double-blind trial conducted in 399 adults > or = 65 yea

85 In a double-blind trial conducted in Matlab, Bangladesh, wome

86 In this double-blind trial conducted on Pemba Island, Tanzania,

87 pose LUME-Meso is a phase II/III randomized, double-blind trial designed to assess efficacy and safet

88 multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of t

89 enrolled in a randomized placebo-controlled double-blind trial (Eastern Cooperative Oncology Group 3

90 In a multicenter, double-blind trial, eligible adults with acute pericardi

91 This randomized clinical double-blind trial enrolled participants at 2 clinical s

92 A randomized, double-blind trial evaluated citalopram at target doses

93 s phase III, randomized, placebo-controlled, double-blind trial evaluated gefitinib plus paclitaxel a

94 This randomized, double-blind trial evaluated the efficacy and safety of

95 This double-blind trial evaluated the safety and efficacy of

96 ansplantation) was a randomized, controlled, double-blind trial evaluating the effect of etanercept v

97 l Infarction (TIMI) 12 trial was a phase II, double-blind trial evaluating the effects of sibrafiban,

98 mpted and the first prospective, randomized, double-blind trials ever performed in transplantation.

99 DESIGN, SETTING, AND PARTICIPANTS: Double-blind trial examining changes in the neural circu

100 In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we

101 elapse was modest (NNT=17), but confirmed in double-blind trials, first- and multi-episode patients,

102 either IMT (n = 38) or placebo (n = 37) in a double-blind trial for six months, with continuation of

103 Few double-blind trials have compared longer-term efficacy a

104 We did a parallel-group, randomised, double-blind trial in 11 secondary and two primary care

105 1 week, in a placebo-controlled, randomized, double-blind trial in 60 patients with bipolar depressio

106 In a double-blind trial in Dar es Salaam, Tanzania, we random

107 We did a prospective, randomised, double-blind trial in Europe and Israel in 6321 patients

108 This study was a randomized, double-blind trial in patients aged >18 years with ABSSS

109 We performed a 15- to 24-month, multicenter, double-blind trial in patients with advanced Parkinson d

110 This was a 39-center, double-blind trial in patients with definite MS of any c

111 undertook a randomised, placebo-controlled, double-blind trial in three South African sites in sexua

112 e inhibitors were evaluated in a randomized, double-blind trial in which 20 HIV-infected subjects on

113 postmenopausal women participated in a 6-mo double-blind trial in which 40 g protein as part of a Na

114 We conducted a prospective, double-blind trial in which 7232 patients were randomly

115 We conducted a randomized, double-blind trial in which adults with acute bacterial

116 ENGAGE AF-TIMI 48 was a randomised, double-blind trial in which patients with atrial fibrill

117 ed phase 2, multicentre, placebo-controlled, double-blind trials in patients with advanced or incurab

118 erformed a pooled analysis of data from four double-blind trials in which 1748 patients were randomly

119 d patient-level database from 4 prospective, double-blind trials in which 3445 patients were randomiz

120 eluting stents or bare-metal stents and five double-blind trials in which 3513 patients were randomly

121 studied in a randomized, placebo-controlled, double-blinded trial in 110 human immunodeficiency virus

122 asma specimens obtained during a randomized, double-blinded trial in antiretroviral therapy (ART)-nai

123 valuation (MORE), a multicenter, randomized, double-blind trial, in which women taking raloxifene or

124 This monocentric, placebo-controlled, double-blind trial included 132 patients with grass poll

125 This randomised double-blind trial included 9270 patients with chronic k

126 Community-based, prospective, randomized, double-blind trial including 1702 men and women with no

127 In a randomized, multicenter, double-blind trial, inhaled iloprost (5 mug) or placebo

128 ildren were enrolled in a placebo-controlled double-blind trial investigating the effects of growth h

129 In a randomized, double-blind trial involving 135 patients with severe eo

130 The Pediatric Heart Network conducted a double-blind trial involving 230 infants with single-ven

131 We conducted a 56-week, double-blind trial involving 3731 patients who did not h

132 In this multicenter, randomized, double-blind trial involving 459 patients, clinically im

133 We conducted a multicenter, randomized, double-blind trial involving nulliparous women who were

134 We conducted a multicenter, prospective, double-blind trial involving outpatient adults and child

135 In a double-blind trial involving patients with end-stage ren

136 In two multicenter, randomized, double-blind trials involving 448 patients with ARDS fro

137 For non-double-blinded trials larger than 200 participants, inve

138 Five randomized double-blind trials lasted 12-16 weeks and treated 1,293

139 In a randomized, double-blind trial, male and female opioid-dependent pat

140 We conducted a long-term, double-blind trial (mean follow-up, 4.5 years) involving

141 ll patients exposed to ranolazine during the double-blind trials (n = 972) preceding the ROLE program

142 f age) were initially randomly assigned to a double-blind trial of 12 once-weekly subcutaneous inject

143 We performed a double-blind trial of 204 patients (78% Caucasian; 67% f

144 DESIGN, SETTING, AND PATIENTS: Randomized, double-blind trial of 300 women aged 18 to 55 years with

145 In a double-blind trial of 352 patients with anterior MI, we

146 We conducted a randomized, double-blind trial of 383 patients who had a first acute

147 , we conducted a single-center, prospective, double-blind trial of 39 patients with mucinous-type pan

148 rtraline were randomly assigned to a 28-week double-blind trial of 50-200 mg/day of sertraline or pla

149 nrolled in a randomized, placebo-controlled, double-blind trial of a nonselective beta-blocker used t

150 first large, randomized, placebo-controlled, double-blind trial of a statin with standard-of-care for

151 We performed a prospective double-blind trial of adult patients with a recent (<8 w

152 olled in a national multicenter, randomized, double-blind trial of an acellular pertussis vaccine.

153 As part of a randomized, double-blind trial of antifungal prophylaxis in liver tr

154 A multicenter, randomized, double-blind trial of aspirin (300 mg/day) and folate su

155 We performed a randomized, double-blind trial of aspirin as a chemopreventive agent

156 Conclusion In this prospective, randomized, double-blind trial of ATLG in unrelated myeloablative HC

157 -year, prospective, multicenter, randomized, double-blind trial of early CCS withdrawal in 386 kidney

158 ndred forty-six CAE children in a randomized double-blind trial of ethosuximide, lamotrigine, and val

159 In a randomized, placebo-controlled, double-blind trial of exemestane designed to detect a 65

160 Two-year, randomized, placebo-controlled, double-blind trial of intra-articular triamcinolone vs s

161 openia) in a randomized, placebo-controlled, double-blind trial of levofloxacin (P = .01).

162 -targeted sunitinib therapy in a randomized, double-blind trial of metastatic castration-resistant pr

163 multicenter, randomized, placebo-controlled, double-blind trial of New York Heart Association class I

164 A multicenter, prospective, randomized, double-blind trial of P withdrawal at 3 months post-tran

165 We performed a phase 3, double-blind trial of patients who completed golimumab i

166 We then performed a double-blind trial of patients with IBS (mean age, 31 y;

167 We conducted a single-center, randomized, double-blind trial of perioperative subcutaneous pasireo

168 This was a randomized, double-blind trial of placebo and three alternative regi

169 multicenter, randomized, placebo-controlled, double-blind trial of placebo versus nasal mometasone in

170 BIG 1-98 is a randomised, phase 3, double-blind trial of postmenopausal women with hormone

171 trial was a randomized, placebo-controlled, double-blind trial of ranitidine 300 mg (orally twice da

172 le Angina) was an international, randomized, double-blind trial of ranolazine versus placebo in patie

173 We conducted a prospective, randomized, double-blind trial of rifapentine at three doses (600, 9

174 We conducted a multisite, randomized, double-blind trial of risperidone as compared with place

175 data from a previously reported, randomized, double-blind trial of standard- versus low-dose lithium

176 We did a randomised, placebo-controlled, double-blind trial of the effect of intermittent prevent

177 We conducted a randomized, double-blind trial of the effect of supplementation with

178 We performed a multicenter, randomized, double-blind trial of the efficacy and safety of 400, 80

179 hin-subjects, randomized, placebo-controlled double-blind trial of the nicotinic agonist AZD3480 (als

180 We conducted a placebo-controlled, double-blind trial of the prophylactic effect of vitamin

181 ients enrolled in a prospective, randomized, double-blind trial of traumatic hypovolemic shock, HSD (

182 We conducted a randomized, double-blind trial of treatment with either 200 mg of it

183 and August 2010, we conducted a randomized, double-blind trial of twice daily 500 mg valacyclovir or

184 liter) in a randomized, placebo-controlled, double-blind trial of up to three 26-day courses of trea

185 were recruited for a randomized, controlled, double-blind trial of vitamin D supplementation in pregn

186 wheat bran fiber (WBF) study, a randomized, double-blind trial of WBF as a means of decreasing the p

187 ysis of data from two replicate, randomised, double-blind trials of 12 months' duration (Sept 25, 200

188 che-sponsored randomised placebo-controlled, double-blind trials of 75 mg twice a day oseltamivir in

189 ndertaking the major investment required for double-blind trials of a potential disease-modifying dru

190 entified, 10 randomized, placebo-controlled, double-blind trials of Gp IIb/IIIa inhibitors in ACSs we

191 We did three phase 1, placebo-controlled, double-blind trials of ZPIV with aluminium hydroxide adj

192 conducted a placebo-controlled, randomized, double-blinded trial of alendronate (10 mg/day orally) (

193 One-year results of a randomized, double-blinded trial of Thymoglobulin versus Atgam for i

194 ned to overcome the shortcomings of previous double-blinded trials of household water treatment in lo

195 In this randomized, double-blind trial, outpatients with schizophrenia (n=55

196 In this phase 3, randomised, double-blind trial, patients were enrolled across 141 si

197 In this double-blind trial, patients were randomized to receive

198 In a double-blind trial, patients were randomized to tolvapta

199 In this phase 3, double-blind trial, patients were randomly assigned (1:1

200 In this phase 3, double-blind trial, patients were randomly assigned (2:1

201 These three multicenter, prospective, double-blind trials performed at 55 transplant centers o

202 ek, phase 3, randomized, placebo-controlled, double-blind trials performed from July 15, 2010, to Apr

203 he DAPT (Dual Antiplatelet Therapy) Study, a double-blind trial, randomly assigned 11 648 patients wh

204 (There are no large, prospective, randomized double-blind trials testing the efficacy of IE prophylax

205 In a randomized, placebo-controlled, double-blind trial, thalidomide or placebo together with

206 ial 2) was a randomized, placebo-controlled, double-blind trial that assessed the effects of fludroco

207 spirin with a COX-2 selective inhibitor in a double-blind trial that compared placebo, low-dose aspir

208 EVATE-TIMI 56 was a multicenter, randomized, double-blind trial that enrolled and genotyped 333 patie

209 The BIG 1-98 trial is a double-blind trial that randomly assigned 6,193 postmeno

210 TART trial was an international, randomised, double-blind trial that recruited patients with unresect

211 isperidone and olanzapine were compared in a double-blind trial that used doses widely accepted in cl

212 In this double-blind trial, the infants were randomly assigned t

213 aucity of data from randomized, prospective, double-blind trials, the effect of n-3 fatty acids on de

214 We did a randomised, double-blind trial to assess the usefulness of sibutrami

215 conducted a randomized, placebo-controlled, double-blind trial to assess whether use of the selectiv

216 Subjects were randomized in this double-blind trial to atorvastatin 80 mg/d or placebo fo

217 We undertook a randomised double-blind trial to compare the effectiveness of chlor

218 We did a phase 1 double-blind trial to compare the safety and immunogenic

219 conducted a randomized, placebo-controlled, double-blind trial to determine if UDCA (10-15 mg/kg/d)

220 We conducted a randomized, double-blind trial to determine the effect of aspirin on

221 conducted a randomized, placebo-controlled, double-blind trial to establish the efficacy of atovaquo

222 We conducted a randomized, double-blind trial to evaluate intravenous benzodiazepin

223 We performed a placebo-controlled, phase 3, double-blind trial to evaluate the efficacy and safety o

224 Aspirin Recurrent Stroke Study, a randomized double-blind trial to evaluate the efficacy of warfarin

225 orvastatin 80 mg vs. 10 mg in a multicenter, double-blind trial to evaluate the impact of atorvastati

226 We conducted a double-blind trial to evaluate this therapeutic approach

227 We conducted a randomized, double-blind trial to examine the effect of celecoxib on

228 did a prospective, multicentre, randomised, double-blind trial to investigate the impact of the addi

229 Randomized, double-blind trial (treatment period, 18 months; median

230 This multicenter, randomized, partially double-blind trial used a factorial design to compare pa

231 A randomized, double-blind trial was conducted at ambulatory care cent

232 A randomized, double-blind trial was conducted in 189 volunteers aged

233 A randomized, double-blind trial was conducted in 4 countries (Afghani

234 itoneal dialysis, a multicenter, randomized, double-blind trial was conducted in 92 patients (control

235 This prospective, randomized, double-blind trial was conducted to compare clinafloxaci

236 his prospective, randomized, controlled, and double-blind trial was conducted to compare the safety a

237 This international, multicenter double-blind trial was designed to compare the therapeut

238 This double-blind trial was designed to test the hypothesis t

239 A multicenter prospective randomized double-blind trial was performed in 856 high-risk patien

240 The double-blind trial was terminated early because buprenor

241 This double-blind trial was undertaken in 255 sites in 30 cou

242 A randomized, double-blind trial was undertaken to measure the effects

243 This parallel group, semirandomized double-blinded trial was conducted in a single center in

244 A prospective, randomized (1:1), double-blinded trial was conducted with 100 subjects.

245 A randomized-order, crossover, double-blinded trial was performed in 14 healthy postmen

246 A double-blinded trial was performed involving 29 nonhypox

247 CTN) 0802, a phase 3 multicenter randomized double-blinded trial, was designed to test whether mycop

248 In this 52-week, randomized, double-blind trial, we assessed efficacy and augmentatio

249 In this randomized, double-blind trial, we assessed the efficacy and safety

250 In a multicenter, randomized, double-blind trial, we assessed two treatments for early

251 In a randomized, double-blind trial, we assigned 11,506 patients with hyp

252 In this randomized, double-blind trial, we assigned 2278 patients with systo

253 In this randomized, double-blind trial, we assigned 3445 patients with sympt

254 n an international, multicenter, randomized, double-blind trial, we assigned critically ill adults to

255 In this randomized, double-blind trial, we compared 4 years of therapy with

256 In this randomized, double-blind trial, we compared apixaban (at a dose of 5

257 In this randomised, double-blind trial, we compared degree of pain between s

258 In this randomized, double-blind trial, we compared parenteral amiodarone, l

259 In a randomized, double-blind trial, we compared tenecteplase plus hepari

260 In a randomized, double-blind trial, we compared the drug-coated stent wi

261 In a double-blind trial, we compared the effect of the angiot

262 In our prospective randomised double-blind trial, we enrolled adults (>40 years) with

263 this international, multicentre, randomised, double-blind trial, we enrolled patients aged 18-65 year

264 his phase 2, placebo-controlled, randomized, double-blind trial, we evaluated a vaccine consisting of

265 In this multicenter, randomized, double-blind trial, we evaluated the efficacy and safety

266 In this double-blind trial, we examined the possibility that ras

267 In a prospective, multicenter, double-blind trial, we randomized 2,466 high bleeding ri

268 In a two-site, double-blind trial, we randomized 42 adult patients with

269 In a double-blind trial, we randomly assigned 14,264 patients

270 In a double-blind trial, we randomly assigned 15,828 patients

271 In this multicenter, double-blind trial, we randomly assigned 180 patients wi

272 In a three-month, double-blind trial, we randomly assigned 209 patients wi

273 In this double-blind trial, we randomly assigned 2157 patients w

274 In this double-blind trial, we randomly assigned 225 men over th

275 In this multicenter, double-blind trial, we randomly assigned 3876 patients w

276 In this double-blind trial, we randomly assigned 8442 patients w

277 In a 24-week, double-blind trial, we randomly assigned 89 patients wit

278 In a randomized, double-blind trial, we randomly assigned a total of 213

279 In a prospective, double-blind trial, we randomly assigned patients underg

280 In this double-blind trial, we randomly assigned patients with i

281 In this double-blind trial, we randomly assigned patients with t

282 In this multicenter, placebo-controlled, double-blind trial, we randomly assigned women at immine

283 In this phase 3, randomised, double-blind trial, we recruited eligible patients with

284 multicenter, placebo-controlled, randomized, double-blind trial, we showed that acquired infections i

285 In a two-year double-blind trial, we studied the effect of 10 mg of al

286 In two double-blind trials, we randomly assigned patients to re

287 Among women participating in a randomized, double-blinded trial, we assessed the effect of periodic

288 Primary outcomes after the double-blind trial were full relapse, dropout due to rel

289 resent, prospective, randomized multicenter, double-blind trial were to compare the efficacy of the m

290 The results from 2 parallel-design, double-blind trials were combined.

291 Two phase 3 randomized, double-blind trials were conducted at 154 sites in the U

292 Grantcharov and colleagues did a randomised double-blind trial which showed that training by virtual

293 In this phase 3, double-blind trial, which was conducted at 133 centers w

294 e investigated during a 6-mo parallel-group, double-blind trial with 3 interventions.

295 opausal women during a 6-mo, parallel-group, double-blind trial with 3 interventions.

296 performed a randomized, placebo-controlled, double-blind trial with 48 obese participants and used f

297 In this eight-center, randomized, double-blind trial with a 2-by-2 factorial design, we co

298 s and amiodarone, a multicenter, randomized, double-blind trial with cardiovascular outcomes that com

299 testinal bleeding in a prospective, phase 3, double-blind trial with parallel omeprazole suspension a

300 We conclude that double-blinded trials with consistent application of mea